First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Fiche publication
Date publication
juin 2015
Journal
Annals of oncology : official journal of the European Society for Medical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr ZANETTA Sylvie
Tous les auteurs :
Ravaud A, Oudard S, De Fromont M, Chevreau C, Gravis G, Zanetta S, Theodore C, Jimenez M, Sevin E, Laguerre B, Rolland F, Ouali M, Culine S, Escudier B
Lien Pubmed
Résumé
Papillary renal cell carcinoma (PRCC), type 1 and type 2, represents 10%-15% of renal cell carcinomas (RCC). There is no standard first-line treatment of metastatic PRCC (mPRCC). Anti-angiogenics have shown activity in retrospective studies but no prospective studies in pure papillary histology have been reported, but one with foretinib.
Mots clés
anti-angiogenic, papillary renal cell carcinoma, renal cell carcinoma, sunitinib, type 1 papillary renal cell carcinoma, type 2 papillary renal cell carcinoma
Référence
Ann. Oncol.. 2015 Jun;26(6):1123-8